MOMECOR CREAM

Mometasone furoate exhibits marked anti-inflammatory activity and marked anti-psoriatic activity in standard animal predictive models.

Pharmacokinetic studies have indicated that systemic absorption following topical application of mometasone furoate cream 0.1% is minimal, approximately 0.4% of the applied dose in man, the majority of which is excreted within 72 hours following application. Characterization of metabolites was not feasible owing to the small amounts present in plasma and excreta.

A thin film of Mometasone Furoate 0.1% w/w Cream should be applied to the affected areas of skin once daily. Method of administration One fingertip unit (a line from the tip of an adult index finger to the first crease) is enough to cover an area twice the size of an adult hand. Use of topical corticosteroids in children or on the face should be limited to the least amount compatible with an effective therapeutic regimen, and duration of treatment should be no more than 5 days.

MOMECOR Cream is available in 15 g of pack filled in laminated tube & packed in Carton.